典型文献
Effect of treatment with Fufang Huangqi decoction(复方黄杞汤剂)on dose reductions and discontinuation of pyridostigmine bromide tablets,prednisone,and tacrolimus in patients with type Ⅰ or Ⅱ myasthenia gravis
文献摘要:
OBJECTIVE:To investigate the clinical efficacy of Fufang Huangqi decoction(复方黄杞汤剂)in combination with pyridostigmine bromide tablets,prednisone,and tacrolimus in the treatment of type Ⅰ and Ⅱ myasthenia gravis(MG)through changes in the clinical symptom scores of 100 patients with type Ⅰ and Ⅱ MG.This study also aimed to examine dose reductions and dis-continuation of these 3 Western medicines after administration of Fufang Huangqi decoction.METHODS:The clinical data on 100 patients with type Ⅰor Ⅱ MG who were treated in the outpatient department of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,China,between June 2017 and June 2020 were collected.The patients were divided into 4 groups based on whether they had taken pyridostigmine bromide tablets,prednisone,and/or tacrolimus at the time of their hospital visit:the Fufang Huangqi decoction group(group A),the pyridostigmine bromide tablets+Fufang Huangqi decoction group(group B),the pyridostigmine bromide tablets+prednisone+Fufang Huangqi decoction group(group C),and the pyridostigmine bromide tablets+tacrolimus+Fufang Huangqi decoction group(group D).The average treatment time was(15.6±11.5)months(range:0.5-55 months).Changes in the clinical symptom scores of the 4 groups of patients after medication administration and dose reductions and discontinuation of the 3 Western medicines were analyzed.RESULTS:An overall effectiveness rate of 86.00%was achieved in the 100 patients after treatment for(15.6±11.5)months(range 0.5-55 months).The effectiveness rates were 85.71%in group A,88.24%in group B,76.92%in group C,and 80.00%in group D.The dosage of pyridostigmine bromide was reduced for 69.12%of the patients in group B for the first time after(4.2±4.1)months,and 45.59%of the patients in group B discontinued pyridostigmine bromide after(8.8±6.1)months.The dosage of pyridostigmine bromide was reduced for 46.15%of the patients in group C for the first time after(5.3±3.4)months,and 23.08%of the patients in group C discontinued pyridostigmine bromide after(19.8±11.0)months;76.92%reduced hormone dosage after(2.8±1.9)months,and 23.08%discontinued hormone treatment after(6.7±2.9)months.The dosage of pyridostigmine bromide was reduced for 1 patient in group D after 1 month;this patient discontinued pyridostigmine bromide after 3 months and reduced tacrolimus dosage after 5 months.One patient in group D discontinued pyridostigmine bromide and tacrolimus on his own initiative at 0.5 months and took Fufang Huangqi decoction for 2 months without discontinuing Western medicine.CONCLUSION:Fufang Huangqi decoction is effective for the treatment of type Ⅰ and Ⅱ MG and improves the associated clinical symptoms.Moreover,this agent is conducive to dose reductions and discontinuation of basic Western medicines,thereby reducing the side effects experienced by patients.
文献关键词:
中图分类号:
作者姓名:
SHAN Caifeng;ZHANG Jingsheng;LIN Yi;HUANG Xueshi;WANG Zhanyou;PAN Haiou;QIAO Wenjun
作者机构:
the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Liaoning Provincial Key Laboratory for Diagnosis and Treatment of Myasthenia Gravis,Liaoning University of Traditional Chinese Medicine,Shenyang 110033,China;Department of General Surgery,the First People's Hospital of Shenyang,Shenyang 110091,China;Institute of Microbial Pharmaceuticals,College of Life and Health Sciences,Northeastern University,Shenyang 110819,China;Institute of Health Sciences,Key Laboratory of Medical Cell Biology of Ministry of Education,China Medical University,Shenyang 110122,China;Liaoning University of Traditional Chinese Medicine,foreign language college,Liaoning University of Traditional Chinese Medicine,Shenyang 110033,China
文献出处:
引用格式:
[1]SHAN Caifeng;ZHANG Jingsheng;LIN Yi;HUANG Xueshi;WANG Zhanyou;PAN Haiou;QIAO Wenjun-.Effect of treatment with Fufang Huangqi decoction(复方黄杞汤剂)on dose reductions and discontinuation of pyridostigmine bromide tablets,prednisone,and tacrolimus in patients with type Ⅰ or Ⅱ myasthenia gravis)[J].中医杂志(英文版),2022(05):810-817
A类:
pyridostigmine,tablets+Fufang,tablets+prednisone+Fufang,tablets+tacrolimus+Fufang,discontinuing
B类:
Effect,treatment,Huangqi,decoction,黄杞,汤剂,dose,reductions,discontinuation,bromide,patients,type,myasthenia,gravis,OBJECTIVE,To,investigate,clinical,efficacy,combination,MG,through,changes,scores,This,study,also,aimed,examine,these,medicines,after,administration,METHODS,data,who,were,treated,outpatient,department,Affiliated,Hospital,Liaoning,University,Traditional,Chinese,Medicine,China,between,June,collected,divided,into,groups,whether,they,had,taken,their,hospital,visit,average,was,months,range,Changes,medication,analyzed,RESULTS,An,overall,effectiveness,achieved,rates,dosage,reduced,first,discontinued,hormone,this,One,own,initiative,took,without,CONCLUSION,improves,associated,symptoms,Moreover,agent,conducive,basic,thereby,reducing,side,effects,experienced
AB值:
0.26586
相似文献
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。